Incyte announces Phase 3b TRuE-AD4 study met co-primary endpoints

Incyte (INCY) announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura in adults with moderate atopic dermatitis, AD, who had an inadequate response, intolerance or contraindication to topical corticosteroids, TCSs, and topical calcineurin inhibitors, TCIs. These data will be presented during the Systemic and New Therapies for Atopic Dermatitis session on Sunday, October 26 at 10:55 a.m. AEDT at the 15th Georg Rajka International Symposium on Atopic Dermatitis, ISAD, held from October 24 – 26, 2025, in Melbourne. Data from TRuE-AD4, which build on previously announced topline results, show the study met its co-primary endpoints at Week 8, with a statistically significant proportion of patients achieving both a greater than or equal to75% improvement in Eczema Area and Severity Index score from baseline and Investigator’s Global Assessment Treatment Success. Patients treated with Opzelura demonstrated improvement in EASI75 and IGA-TS at Week 2. More patients treated with Opzelura achieved both EASI75 and IGA-TS at Week 8 than vehicle.